Accurate developability assessments of antibody candidates with the IGX Platform
Discover how you can use structural modeling to identify antibody liabilities and developability profiles for thousands of sequences at once.
Discover how you can use structural modeling to identify antibody liabilities and developability profiles for thousands of sequences at once.
The new IGX-Track App expands the capabilities of the IGX Platform by adding seamless analysis of antibody panning campaigns.
Genovac, a leading CRO/CMO that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments, will utilize ENPICOM’s IGX Platform for antibody discovery workflows.
Now powered by AWS, ENPICOM can further accelerate scientific breakthroughs and enable scientists to harness the latest scientific advances.
Discover how you can perform advanced phylogenetic analysis, understand B cell lineages and the affinity maturation process to expand your antibody candidate pool.
ENPICOM has secured funding from BOP Capital to support the growth of their unique SaaS platform for therapeutic antibody discovery.
Inno4vac is a new interdisciplinary project funded by the Innovative Medicines Initiative 2 that aims to foster health innovation by incorporating scientific and technological breakthrough from the academic and biotech sectors into industry.
The IGX Platform empowers researchers to accurately predict exposed liabilities for thousands of sequences at the same time using high-throughput structural modeling.
The Florijnz Data Science Top 50 report is out! We’re excited to be recognized as one of the fastest-growing players in the Data Science market for small and medium-sized enterprises in the Netherlands.
The IGX Platform integrates SAbPred, developed at the University of Oxford, to support high-throughput de-risking of antibody discovery.